

10/ 635977

#00FC  
D0283A CIP**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico  
Type or print name

  
Signature

11-3-06  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

JOHN FEDER, ET AL

PATENT NO: 7122358

FILED: 08/07/2003

FOR: POLYNUCLEOTIDES ENCODING A NOVEL TESTIS-SPECIFIC  
TUBULIN TYROSINE-LIGASE-LIKE PROTEIN, BGS42

**Certificate of Corrections Branch**  
**Commissioner for Patents**  
**PO BOX 1450**  
**Alexandria, VA 22313-1450**

**Certificate**  
NOV 08 2006  
**of Correction**

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT**

Sir:

Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing.

We would like to direct your attention to the following errors:

(75) Inventors: Add "Liana M. Lee"

See Applicant's July 27, 2006 Request to Correct Inventorship under §1.48(a) and §1.312 to add Liana M. Lee as an inventor.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Column 323 - What is claimed is:

11/07/2006 MBIZUNES 00000039 7122358

Claim 10, line 46, second word on this line should be "a"

01 FC:1811

100.00 DA

Claim 10, line 46, should now read "using a CLUSTALW global sequence alignment using default"

NOV - 9 2006

See Applicant's Claim 30 as presented in Applicant's May 22, 2006 Reply.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Column 324

Claim 14, line 16, "glutamie" should read "glutamic"

See Applicant's Claim 34 as presented in Applicant's May 22, 2006 Reply.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Claim 15, line 19, "serin" should read "serine"

See Applicant's Claim 35 as presented in Applicant's May 22, 2006 Reply.

We believe this error occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322.

Claim 17, line 25, delete "encoded"

We believe this error occurred through the fault of Applicants, for which correction is sought under 37 CFR 1.323.

Claim 18, line 37, delete "polynucleotide encodes a" and delete "that" after polypeptide

Claim 18 line 37 and 38 should now read "wherein said polypeptide has tubulin tyrosine ligase activity."

We believe this error occurred through the fault of Applicants, for which correction is sought under 37 CFR 1.323.

Applicants submit that these corrections present no new matter and do not require reexamination, as it is clear from the patent document itself that each of the errors is of a typographical, clerical and/or minor nature, and the correct text would be readily apparent to one skilled in the field.


Please charge the fee set forth in §1.20(e) of \$100 to Deposit Account No. 19-3880 of the undersigned.

NOV - 9 2006

The USPTO is requested to kindly contact the undersigned if deemed appropriate to expedite this request.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

  
Stephen C. D'Amico  
Agent for Applicant  
Reg. No. 46,652  
Phone: 609-252-5289  
Date: 11-3-06

NOV - 9 2006

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7122358

APPLICATION NO.: 10/635977

ISSUE DATE : 17/OCT/2006

INVENTOR(S) : FEDER JOHN N, NELSON THOMAS C., WU SHUJIAN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(75) Inventors: Add "Liana M. Lee"

Column 323 - What is claimed is:

Claim 10, line 46, second word on this line should be "a"

Claim 10, line 46, should now read "using a CLUSTALW global sequence alignment using default"

Column 324

Claim 14, line 16, "glutamie" should read "glutamic"

Claim 15, line 19, "serin" should read "serine"

Claim 17, line 25, delete "encoded"

Claim 18, line 37, delete "polynucleotide encodes a" and delete "that" after polypeptide

Claim 18 line 37 and 38 should now read "wherein said polypeptide has tubulin tyrosine ligase activity."

### MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NOV - 9 2006

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7122358

APPLICATION NO.: 10/635977

ISSUE DATE : 17/OCT/2006

INVENTOR(S) : FEDER JOHN N, NELSON THOMAS C., WU SHUJIAN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(75) Inventors: Add "Liana M. Lee"

Column 323 - What is claimed is:

Claim 10, line 46, second word on this line should be "a"

Claim 10, line 46, should now read "using a CLUSTALW global sequence alignment using default"

Column 324

Claim 14, line 16, "glutamie" should read "glutamic"

Claim 15, line 19, "serin" should read "serine"

Claim 17, line 25, delete "encoded"

Claim 18, line 37, delete "polynucleotide encodes a" and delete "that" after polypeptide

Claim 18 line 37 and 38 should now read "wherein said polypeptide has tubulin tyrosine ligase activity."

### MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NOV - 9 2006